Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Moderately Active Ulcerative Colitis

NCT06488625 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

459

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis, Unspecified

Interventions

DRUG: Low-Dose CICR-NAM
DRUG: High-Dose CICR-NAM
DRUG: 0 g/d CICR-NAM (blinded)
DRUG: Open-Label

Sponsor

University Hospital Schleswig-Holstein

Collaborators

[object Object]
[object Object]
[object Object]